Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565902 | 1.00 | PDE3B (0.51) | PDE3BPDE3AHSD17B10NAMPTMAPT | |
| SCHEMBL985935 | 0.85 | HSD17B10 (0.57) | PDE3BPDE3AHSD17B10MAPTAKT1 | |
| SCHEMBL25780156 | 0.84 | HSD17B10 (0.56) | PDE3BPDE3AHSD17B10MAPTAKT1 | |
| SCHEMBL3383472 | 0.84 | HSD17B10 (0.58) | PDE3BPDE3AHSD17B10MAPTMAPK1 | |
| SCHEMBL28734074 | 0.83 | HSD17B10 (0.48) | HSD17B10NAMPTMAPTLMNAALDH1A1 | |
| SCHEMBL3378290 | 0.83 | AKT1 (0.62) | PDE3BPDE3AHSD17B10MAPTAKT1 | |
| SCHEMBL25780858 | 0.82 | HSD17B10 (0.54) | PDE3BPDE3AHSD17B10MAPTAKT1 | |
| SCHEMBL25780664 | 0.82 | HSD17B10 (0.56) | PDE3BPDE3AHSD17B10MAPTAKT1 | |
| SCHEMBL28734098 | 0.82 | MAP4K4 (0.49) | PDE3BPDE3AHSD17B10NAMPTMAPT | |
| SCHEMBL20293286 | 0.82 | HSD17B10 (0.53) | PDE3BPDE3AHSD17B10MAPTAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214287-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023109902-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF IN MEDICINE | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| CN-113214287-A | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2021-08-06 | — | — | CN | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| CN-107922431-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2021-06-04 | — | — | CN | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-3322711-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | University Health Network (CA) | 2018-05-23 | — | — | EP | disclosed |
| WO-2016205942-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2016-12-29 | — | — | WO | disclosed |
| US-8299081-B2 | Methods for treating drug resistant cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| EP-2301546-A1 | Treatment of metastasized tumors | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7838527-B2 | Methods of treating cancer and related methods | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100173873-A1 | TREATMENT OF METASTASIZED TUMORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-08 | — | — | US | disclosed |
| US-20100086518-A1 | TREATMENT OF MELANOMA | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20090215793-A1 | Methods for treating drug resistant cancer | NOVARTIS AG | 2009-08-27 | — | — | US | disclosed |
| WO-2008112509-A1 | TREATMENT OF MELANOMA | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | PDE3B 1903/4885PDE3A 1591/4885HSD17B10 1233/4885 |
| US-20100173873-A1 | TREATMENT OF METASTASIZED TUMORS | VIM, VHL, CA14 | PDE3B 4731/4885PDE3A 4381/4885HSD17B10 3843/4885 |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | PDE3B 1903/4885PDE3A 1591/4885HSD17B10 1233/4885 |
| US-20100086518-A1 | TREATMENT OF MELANOMA | TYR, MITF, MC1R | PDE3B 3938/4885PDE3A 2963/4885HSD17B10 4251/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | PDE3B 1856/4885PDE3A 1544/4885HSD17B10 1201/4885 |
| US-20090215793-A1 | Methods for treating drug resistant cancer | ABCC1, SLC11A2, SLC10A1 | PDE3B 3732/4885PDE3A 3447/4885HSD17B10 831/4885 |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | PDE3B 1903/4885PDE3A 1591/4885HSD17B10 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.